ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "ABOi Heart Transplants Expand Pediatric Pool 12/01/25"
Episode Synopsis
Welcome to Cardiology Today – Recorded December 01, 2025. This episode summarizes 5 key cardiology studies on topics like donor organ availability and waitlist mortality. Key takeaway: ABOi Heart Transplants Expand Pediatric Pool.
Article Links:
Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. (Circulation)
Article 2: Combined heart-lung organ allocation: A glitch in the system. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/
Featured Articles
Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41321238
Summary: Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.
Article 2: Combined heart-lung organ allocation: A glitch in the system.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40935217
Summary: This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.
Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40907841
Summary: This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.
Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40902959
Summary: This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device’s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.
Article 5: ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40846116
Summary: B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group.
Transcript
Today’s date is December 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.
Article number two. Combined heart-lung organ allocation: A glitch in the system. This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.
Article number three. High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.
Article number four. Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction. This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device’s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.
Article number five. A. B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group.
Thank you for listening. Don’t forget to subscribe.
Keywords
donor organ availability, waitlist mortality, pediatric heart transplantation, antiphospholipid antibody titers, antiphospholipid syndrome, chronic thromboembolic pulmonary hypertension, HeartMate three, oxidized phospholipids, transplant policy, bleeding risk, thrombotic complications, acute coronary syndrome, pulmonary endarterectomy, isohemagglutinin titers, heart transplantation, A. B. O. incompatible heart transplant, heart-lung transplantation, polytetrafluoroethylene, organ allocation, left ventricular assist device, lipoprotein(a), alirocumab, major adverse cardiovascular events.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post ABOi Heart Transplants Expand Pediatric Pool 12/01/25 first appeared on Cardiology Today.
Article Links:
Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. (Circulation)
Article 2: Combined heart-lung organ allocation: A glitch in the system. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/aboi-heart-transplants-expand-pediatric-pool-12-01-25/
Featured Articles
Article 1: Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome.
Journal: Circulation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/41321238
Summary: Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.
Article 2: Combined heart-lung organ allocation: A glitch in the system.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40935217
Summary: This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.
Article 3: High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40907841
Summary: This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.
Article 4: Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40902959
Summary: This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device’s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.
Article 5: ABO-incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant?
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40846116
Summary: B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group.
Transcript
Today’s date is December 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes after Acute Coronary Syndrome. Researchers measured oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a) levels in 11630 participants with acute coronary syndrome. These markers were quantified at baseline, and in 5185 participants four months after randomization to alirocumab or placebo in the ODYSSEY OUTCOMES trial. This comprehensive analysis established the presence and levels of these pro-inflammatory lipid markers in a large cohort of acute coronary syndrome patients undergoing specific contemporary treatment strategies.
Article number two. Combined heart-lung organ allocation: A glitch in the system. This study found that patients awaiting combined heart-lung transplantation experience unnecessarily long wait times due to the absence of a specific organ allocation system for this patient population. Researchers observed these prolonged wait times following recent revisions to the United States heart and lung allocation systems. The current guidelines prioritize patients based on waitlist mortality, yet combined heart-lung transplant recipients are not adequately prioritized within these separate systems.
Article number three. High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study. This retrospective observational study collected data on patients undergoing pulmonary endarterectomy to investigate outcomes in those with and without antiphospholipid syndrome. The researchers specifically focused on high antiphospholipid antibody titers and their association with post-operative mortality and thrombotic complications. This investigation demonstrated the importance of evaluating antiphospholipid antibody titers for outcomes in chronic thromboembolic pulmonary hypertension patients undergoing surgical intervention.
Article number four. Safe Practices: Partial Coverage of Left Ventricular Assist Device Reduces Bleeding Risk during Explant-Heart Transplant without Causing Obstruction. This single institution study found that partial polytetrafluoroethylene protective coverage of the outflow graft and chassis during HeartMate three left ventricular assist device implant significantly reduced perioperative blood loss during explant-heart transplantation. The data demonstrated that this partial coverage method did not cause obstruction during the device’s function. This safe practice provides a direct clinical benefit by mitigating the challenging intraoperative and postoperative blood loss associated with left ventricular assist device explant procedures.
Article number five. A. B. O. incompatible heart transplants in children aged 2-9 years: A new paradigm in transplant? This study reported on the institutional practice of performing A. B. O. incompatible heart transplants in children aged two to nine years. The center successfully expanded the donor pool for pediatric heart transplantation by considering candidates with isohemagglutinin titers of 1:32 or less for A. B. O. incompatible donors. This approach demonstrated the clinical utility of A. B. O. incompatible heart transplantation beyond infancy, addressing the limited availability of donor organs in this critical age group.
Thank you for listening. Don’t forget to subscribe.
Keywords
donor organ availability, waitlist mortality, pediatric heart transplantation, antiphospholipid antibody titers, antiphospholipid syndrome, chronic thromboembolic pulmonary hypertension, HeartMate three, oxidized phospholipids, transplant policy, bleeding risk, thrombotic complications, acute coronary syndrome, pulmonary endarterectomy, isohemagglutinin titers, heart transplantation, A. B. O. incompatible heart transplant, heart-lung transplantation, polytetrafluoroethylene, organ allocation, left ventricular assist device, lipoprotein(a), alirocumab, major adverse cardiovascular events.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • FollowThe post ABOi Heart Transplants Expand Pediatric Pool 12/01/25 first appeared on Cardiology Today.
In God we trust